Krug S, et al. - Among 51 patients with gastroenteropancreatic neuroendocrine neoplasms (GEP-NEN) and bronchopulmonary NEN (other than small cell lung cancer), researchers assessed median overall survival (mOS) and mOS following the diagnosis of brain metastases (BM) via Kaplan-Meier analysis. They also used univariate and multivariate Cox regression method to determine risk factors for poor prognosis. In GEP-NEN and bronchopulmonary NEN patients, they reported a low risk for symptomatic brain metastases. Median OS after initial diagnosis and diagnosis of BM was 23.0 and 11.0 months, respectively. The overall survival could worsen with age above 60 and poor tumor differentiation. Hence, neuroendocrine carcinoma patients could be recommended to undergo screening for brain metastases.